There are a crazy number of drugs and devices that are promising, safe and effective, but never make it to market for a variety of reasons including study/design failures, finances, poor leadership, internal/external road blocks, emerging competition, poor overall projected ROI relative to other options, changes in the marketplace/space. 

We, obviously, have many of these red flags.

I do still believe apabetalone will get there, at some point, hopefully within the next few years and prior to the BP world catching up with equivalent or better options. The RVX science and opportunities now and into the future with epigenetics and the RVX library are unlimited, potentially.

I don't even really care that much about dilution anymore, as long as stock issue isn't allowing a collaborative majority to risky entities or groups. However the financing to the finish line occurs (for the most part), it just needs to occur. The most important thing is to survive and advance. There is actually so little RVX existing stock now (275-300m shares? ish?) relative to the "value proposition" and entirety of the projected opportunities.

BoM was within an eye lash of the PPS jumping us to the corner of High Street and Electric Avenue, in Funky Town. And BoM2 looks and seems to be designed to make up for much more than an eye lash of difference, along with Covid, PAH, in the near term in addition to numerous other opportunities.

Keep the faith, what's left of it, think "how" and not about the pain of the jorney. All I care about is for the BoD and Don to find a way to take us ... "all the way to the moon" ... however and whatever it takes. Just get it done.